The impact of nirmatrelvir-ritonavir in reducing hospitalizations among high-risk patients with SARS-CoV-2 during the omicron predominant era
MM Al-Obaidi, AB Gungor, S Murugapandian… - The American Journal of …, 2023 - Elsevier
Background The coronavirus disease 2019 (COVID-19) pandemic has caused significant
morbidity and mortality in high-risk populations. Several therapeutics have been developed
to reduce the risk of complications related to COVID-19, hospitalizations, and death. In
several studies, nirmatrelvir-ritonavir (NR) was reported to reduce the risk of hospitalizations
and death. We aimed to evaluate the efficacy of NR in preventing hospitalizations and death
during the Omicron predominant period. Methods We retrospectively evaluated patients from …
morbidity and mortality in high-risk populations. Several therapeutics have been developed
to reduce the risk of complications related to COVID-19, hospitalizations, and death. In
several studies, nirmatrelvir-ritonavir (NR) was reported to reduce the risk of hospitalizations
and death. We aimed to evaluate the efficacy of NR in preventing hospitalizations and death
during the Omicron predominant period. Methods We retrospectively evaluated patients from …
以上显示的是最相近的搜索结果。 查看全部搜索结果